Indian Iressa purchasing price and sales 18801374745 Indian version of Iressa

('h', More and more lung cancer patients are being treated with the targeted drug Iressa (Indian Iressa). The targeted drug Iressa has become the first choice for the treatment of lung cancer in recent years. Especially the Indian Iressa The launch of Iressa has brought revolutionary hope to the vast number of poor patients to prolong their lives. So what issues should patients first understand when choosing to take Iressa for treatment? Drug Mail has listed several common questions for patients with lung cancer. Reference.
' h', >. What is targeted therapy? How is it different from chemotherapy?
' h', > Targeted therapy acts in a new position compared to traditional chemotherapy. Targeted drug treatment. In fact, chemotherapy and targeted therapy are both drug treatments. Chemotherapy acts on various sites within cells. For example, each cell has different mitosis times. But now on the path of chemotherapy, the original The road to cytotoxic drugs has reached a bottleneck, and it is very difficult to move forward. Many new drugs have not been released. In fact, tumor growth not only involves the mitosis process in cells but also other processes, such as angiogenesis around cells and changes in the environment around cells. The impact of tumors. Malignant tumors require activation, signal transduction, etc. to cause an infinite proliferation process. If this signal transduction is blocked, cell proliferation can be prevented. Drugs developed for these targets are currently popular targeted drugs.
' h', >. What is the role of targeted therapy in the treatment of lung cancer so far?
' h', > At present, the most familiar targeted therapy for lung cancer is Iressa (Indian Iressa) , Tarceva (Indian Tarceva), and Kemena. These three drugs actually have similar mechanisms of action. The basic mechanism is the same. They give patients with (epidermal growth factor) mutations (patients with this target ) has brought about huge changes in the survival period of patients with this type of gene mutation. Their median survival period has increased from about one year to two and a half to three years. This type of drug is very effective in the survival of patients with this type of gene mutation. The prolongation of the lung cancer period is very obvious and is a revolutionary change.
' h', >. Can targeted therapy significantly improve the survival rate of patients? Can it improve the survival rate of all lung cancer patients?
'h', >For some lung cancers, such as patients with positive R mutations who are sensitive to drugs such as Iressa, Tarceva, and Kemena, the improvement in survival is very obvious, and can basically improve the patient's survival. The period of time has doubled or tripled. However, for patients with negative gene mutations and no mutations, our treatment so far has made limited progress, but it is also making progress. Progress is relatively limited. The survival time of such patients is One to one and a half years.
' h', >.Is genetic testing recommended for all lung cancer patients? What kind of genes should be tested first?
' h', >Various conditions If all is allowed, we recommend that all patients be tested. First, the R gene should be tested. The probability of its mutation positivity can reach more than % among people with non-small cell lung cancer in my country. Patients equal to 1/2 are suitable for first-line medication. It may take a long time for patients to wait for genetic testing (two weeks), but the wait is worth it (to determine treatment options). There is also the detection of another type of M fusion gene. If the cell is positive for fusion gene expression, there is also targeted drug treatment, the efficacy of which is similar to the current treatment of patients with R mutation positive by Iressa, Tarceva, and Kemena. , but the total incidence rate in our country is only %. We give priority to R gene testing and then M testing.
' h', >.Which groups of people are more likely to mutate? Is it related to gender, age, and race?
' h', > Among the Caucasian population, the overall chance of mutation is less than ten percent. However, among Chinese people, more than % of all non-small cell lung cancers, and pure adenocarcinoma can reach % mutation. Although Iressa and Tarceva are drugs invented by Western companies, they actually bring far greater benefits to us Chinese than to Westerners. Some people call them God’s gift to the Chinese. From the perspective of the population, generally the mutation rate of women, non-smokers, and patients with adenocarcinoma can even be as high as 60 to 70%. These patients are highly mutated. In addition, some older people may have a mutation rate higher than The mutation rate of some younger people is higher, and the mutation rate of those over 10 years old is higher than that of those under 10 years old.
' h', >.What are the commonly used drugs for targeted treatment of lung cancer so far?
' h', >There are several types of targeted drugs for lung cancer, one is generic drugs. The most typical of these are R gene mutation drugs, including the just-mentioned Iressa, Tarceva, and the domestically produced Kemena. There is also a type of monoclonal antibody drugs that has been ignored by everyone. Monoclonal antibodies that act outside the cell membrane are also drugs that block this pathway. There are also anti-angiogenic drugs such as Avastin. However, these drugs need to be combined with chemotherapy and must be strictly limited. Any drug must be taken under the guidance of a professional doctor as it has its associated toxicity and side effects. The doctor will definitely tell you about the benefits you will get from it and the related side effects and risks. It will be treated after weighing it up and under monitoring. It is not a simple medication.
' h', >. How is the course of targeted therapy for lung cancer determined?
' h', >Targeted therapy is currently represented by drugs such as Iressa, Tarceva, and Kemena, which are taken once a day. The current process is to take it for a month to see the efficacy and whether there are tumors. growth, if the tumor grows in one month, we think this drug is ineffective. For patients whose tumors do not grow or whose tumors shrink, we advocate taking it until the tumor progresses. There are also anti-angiogenic drugs that are combined with chemotherapy. They will be used at the same time as long as chemotherapy is given. After chemotherapy has been given for a certain period, and economic conditions permit and there are no intolerable side effects, it can be used once a month. When the disease progresses, this is called maintenance therapy.
' h', >. Just after radiotherapy and chemotherapy, some patients have a tendency of tumor shrinkage. For such patients, doctors recommend taking targeted drugs. Is this appropriate?
' h', >This is a very controversial issue, and there is debate among doctors. In principle, if there is a large tumor load, we consider adding anti-drugs in advance. If the efficacy is very good or the patient has poor tolerance or various other circumstances, we can rest for a period of time and wait until the disease progresses before taking anti-drugs. drug. There are also different stages. For example, for patients in stage III and IIIB who undergo radiotherapy and chemotherapy at the same time, the lesions are limited to the radiation field. In fact, it is not recommended for this group of patients to use similar drugs after radiotherapy and chemotherapy. There are some stage IV patients who need to change dressing maintenance under certain circumstances. Doctors need to decide whether to use it based on the specific conditions of the patient. They cannot generalize whether it is yes or no. It also requires analysis by professional doctors.
' h', >. Can targeted therapy for lung cancer be performed at the same time as radiotherapy and chemotherapy?
'h', >Chemotherapy or targeted drug treatment first is decided by the doctor and the patient after discussion. However, simultaneous use is not currently recommended, mainly because it does not increase the efficacy. In addition, it has not been found that giving chemotherapy first and then taking similar drugs after it is ineffective will reduce the efficacy of such drugs. The same is true for radiotherapy and will not affect it. Anti-angiogenic drugs and monoclonal antibody drugs must be combined with chemotherapy to be effective. As for radiotherapy, some drugs are acceptable and no serious adverse reactions have been seen. The combination of lung radiotherapy and similar drugs will not increase research related to radiation pneumonitis. So far, no clear increase in data has been seen. However, after all, the current relevant data and information are not particularly sufficient, but in some specific cases I think there is no problem for some patients to do this when the doctor feels it is necessary.
' h', >. After taking targeted therapy drugs for a few months, the efficacy decreases. Does this mean that drug resistance has developed and the drug should be changed?
' h', >This is also a very controversial issue. What does the decline in efficacy mean? Some lesions may have increased in size, some may have remained unchanged, and some may have shrunk. For example, if a patient takes a drug and the tumor grows from a centimeter to a centimeter, it will be considered effective for the patient and we will continue to take it. But if a tumor suddenly grows from the smallest centimeter to one centimeter, we consider it to be tumor progression. However, there is still debate whether the drug should be stopped immediately or changed.
' h', >.What are the common side effects of targeted therapy?
' h', >The main side effects are rash, diarrhea, and skin itching. But these problems are so minor that there is no special solution. The dermatology department will apply some ointment containing hormone antibiotics. If it is really intolerable and needs to be stopped, we will first change one tablet a day to one tablet every other day and have a look before stopping the medicine. This is a no-brainer. In fact, we do not advocate this, and we are not willing to ask patients to stop taking medicine. After all, lung cancer is life-threatening, and we are still willing to give sufficient doses for a full course of treatment. In fact, the number of patients who discontinue medication because they cannot tolerate the side effects is very small, probably around %%.